Cardiopulmonary complications in chronic liver disease

World Journal of Gastroenterology

Volumn 12, Issue 4, 2006, Pages 526-538

  Møller, Søren ^a,b   Henriksen, Jens H ^a,b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Autonomic dysfunction; Baroreceptors; Cardiomyopathy; Cirrhosis; Hemodynamics; Hepatopulmonary syndrome; Portal hypertension; Portopulmonary hypertension; Vasoactive substances

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANRENONE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOCANNABINOID; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; NATRIURETIC FACTOR; NITRATE; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; RENIN; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR AGENT;

AUTONOMIC DYSFUNCTION; CARDIOMYOPATHY; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR DISEASE; DIASTOLIC BLOOD PRESSURE; EDITORIAL; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEPATOPULMONARY SYNDROME; HOMEOSTASIS; HUMAN; HYPERTENSION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG FUNCTION; MEDICAL RESEARCH; OXYGEN THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PORTAL HYPERTENSION; PORTOCAVAL SHUNT; PORTOSYSTEMIC ANASTOMOSIS; PRESSORECEPTOR REFLEX; PULMONARY HYPERTENSION; QT PROLONGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMIC CIRCULATION; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; VASODILATATION;

EID: 33644892769     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i4.526     Document Type: Editorial

References (170)

1. Møller S, Henriksen JH. In: Arroyo V, Gines P, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease. Malden: Blackwell, 1999: 307-329
2. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, Jimenez W, Gaya J, Rivera F, Rodes J. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-487
3. Groszmann RJ, Jensen JE. Pathophysiology of portal hypertension. In: Kaplowitz N, ed. Liver and Biliary Diseases. 2 ed. Baltimore: Williams & Wilkins, 1996: 551-562
4. Møller S, Wiinberg N, Hernriksen JH. Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology 1995; 22: 88-95
5. Møller S, Bendtsen F, Henriksen JH. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Can J Gastroenterol 2001; 15: 94-106
6. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38 Suppl 1: S69-89
7. Kowalski HJ, Abelmann WH. Mcneely WF, Frank NR, Ellis LB. The cardiac output of normal subjects determined by the dye-injection method at rest and during exercise. Am J Med Sci 1954; 228: 622-625
8. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-1363
9. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-778
10. Groszmann RJ. Nitric oxide and hemodynamic impairment. Digestion 1998; 59 Suppl 2: 6-7
11. Rockey DC. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25: 2-5
12. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478-491
13. Møller S, Henriksen JH. Endothelins in chronic liver disease. Scand J Clin Lab Invest 1996; 56: 481-490
14. Helmy A, Jalan R, Newby DE, Johnston NR, Hayes PC, Webb DJ. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001; 33: 826-831
15. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders: role of the renin-angiotensin-aldosterone system. Semin Liver Dis 1994; 14: 23-34
16. Arroyo V, Claria J, Salo J, Jimenez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994; 14: 44-58
17. Møller S, Henriksen JH. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998; 58: 361-372
18. Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998; 29: 328-341
19. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann RJ, eds. Portal hypertension. Pathophysiology and treatment. 1 ed. Oxford: Blackwell, 1994:17-26
20. Bernardi M, Fornale L, Di Marco C, Trevisani F, Baraldini M, Gasbarrini A, De Collibus C, Zaca F, Ligabue A, Colantoni A. Hyperdynamic circulation of advanced cirrhosis: a reap praisal based on posture-induced changes in hemodynamics. J Hepatol 1995; 22: 309-318
21. Laffi G, Lagi A, Cipriani M, Barletta G, Bernardi L, Fattorini L, Melani L, Riccardi D, Bandinelli G, Mannelli M, La Villa G, Gentilini P. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology 1996; 24: 1063-1067
22. Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J (Clin Res Ed) 1986; 292: 1351-1353
23. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-1157
24. Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997; 17: 505-519
25. Schrier RW, Ecder T. Gibbs memorial lecture. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. Mt inai J Med 2001; 68: 350-361
26. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-541
27. Møller S, Bendtsen F, Schiffer S, Henriksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. Scand J Gastroenterol 1996; 31: 928-933
28. Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol 1997; 26: 1111-1119
29. Guevara M, Gines P, Jimenez W, Sort P, Fernandez-Esparrach G, Escorsell A, Bataller R, Bosch J, Arroyo V, Rivera F, Rodes J. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114: 336-343
30. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N Jr, Sanyal AJ, Kunos G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-832
31. Lee FY, Lin HC, Tsai YT, Chang FY, Lu RH, Hou MC, Li CP, Chu CJ, Wang SS, Lee SD. Plasma substance P levels in patients with liver cirrhosis: relationship to systemic and portal hemodynamics. Am J Gastroenterol 1997; 92: 2080-2084
32. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, Martin-Ruiz R, Arroyo V, Rivera F, Rodes J, Jimenez W. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122: 85-93
33. Farzaneh-Far R, Moore K. Nitric oxide and the liver. Liver 2001; 21: 161-174
34. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114: 344-351
35. McNaughton L, Puttagunta L, Martinez-Cuesta MA, Kneteman N, Mayers I, Moqbel R, Hamid Q, Radomski MW. Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc Natl Acad Sci USA 2002; 99: 17161-17166
36. Tazi KA, Barriere E, Moreau R, Heller J, Sogni P, Pateron D, Poirel O, Lebrec D. Role of shear stress in aortic eNOS upregulation in rats with biliary cirrhosis. Gastroenterology 2002; 122: 1869-1877
37. Churchill MA Jr, Geraci JE, Hunder GG. Musculoskeletal manifestations of bacterial endocarditis. Ann Intern Med 1977; 87: 754-759
38. Lee FY, Colombato LA, Albillos A, Groszmann RJ. N omega-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993; 17: 84-90
39. Niederberger M, Martin PY, Gines P, Morris K, Tsai P, Xu DL, McMurtry I, Schrier RW. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995; 109: 1624-1630
40. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, Masini E, Perfetto F, Tarquini R, Gentilini P, Laffi G. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001; 34: 19-27
41. Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, Webb DJ. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol 2003; 38: 44-50
42. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005; 43: 98-103
43. Gupta S, Morgan TR, Gordan GS. Calcitonin gene-related peptide in hepatorenal syndrome. A possible mediator of peripheral vasodilation? J Clin Gastroenterol 1992; 14: 122-126
44. Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol 1991; 12: 118-123
45. Møller S, Becker U, Schifter S, Abrahamsen J, Henriksen JH. Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1996; 25: 316-328
46. Henriksen JH, Møller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. J Hepatol 1999; 31: 712-718
47. Henriksen JH, Møller S, Schifter S, Abrahamsen J, Becker U. High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems. Gut 2001; 49: 112-118
48. Richards AM, Nicholls MG, Lewis L, Lainchbury JG. Adrenomedullin. Clin Sci 1996; 91: 3-16
49. Fabrega E, Casafont F, Crespo J, de la Pena J, San Miguel G, de las Heras G, Garcia-Unzueta MT, Amado JA, Pons-Romero F. Plasma adrenomedullin levels in patients with hepatic cirrhosis. Am J Gastroenterol 1997; 92: 1901-1904
50. Genesca J, Gonzalez A, Catalan R, Segura R, Martinez M, Esteban R, Groszmann RJ, Guardia J. Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Dig Dis Sci 1999; 44: 372-376
51. Polio J, Sieber CC, Lerner E, Groszmann RJ. Cardiovascular hyporesponsiveness to norepinephrine, propranolol and nitroglycerin in portal-hypertensive and aged rats. Hepatology 1993; 18: 128-136
52. Karatapanis S, McCormick PA, Kakad S, Chin JK, Islam M, Jeremy J, Harry D, McIntyre N, Burroughs AK, Jacobs M. Alteration in vascular reactivity in isolated aortic rings from portal vein-constricted rats. Hepatology 1994; 20: 1516-1521
53. Newby DE, Jalan R, Masumori S, Hayes PC, Boon NA, Webb DJ. Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res 1998; 38: 221-228
54. Moreau R, Komeichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994; 106: 1016-1023
55. Jaue DN, Ma Z, Lee SS. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 1997; 25: 1361-1365
56. Helmy A, Newby DE, Jalan R, Hayes PC, Webb DJ. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003; 52: 410-415
57. Henriksen JH. Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. J Hepatol 1995; 23 Suppl 1: 25-30
58. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, Milicua JM, Jimenez W, Arroyo V. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-447
59. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75-197
60. Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, Casini Raggi V, Foschi M, Marra F, Pinzani M. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993; 104: 588-594
61. Gonzalez-Abraldes J, Albillos A, Banares R, Del Arbol LR, Moitinho E, Rodriguez C, Gonzalez M, Escorsell A, Garcia-Pagan JC, Bosch J. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382-388
62. Møller S, Henriksen JH. Review article: pathogenesis and pathophysiology of hepatorenal syndrome - is there scope for prevention? Aliment Pharmacol Ther 2004; 20 (Suppl 3): 31-41; discussion 42-43
63. Brinch K, Møller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003; 39: 24-31
64. Møller S, Henriksen JH, Bendtsen F. Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol 2003; 284: G970-G979
65. Colombato LA, Albillos A, Groszmann RJ. The role of central blood volume in the development of sodium retention in portal hypertensive rats. Gastroenterology 1996; 110: 193-198
66. Henriksen JH, Bendtsen F, Sorensen TI, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97: 1506-1513
67. Kiszka-Kanowitz M, Henriksen JH, Møller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol 2001; 35: 605-612
68. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R, Urbank A, Butler-Barnes J, Patel N. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-1583
69. Møller S, Bendtsen F, Christensen E, Henriksen JH. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J Hepatol 1994; 21: 940-946
70. Epstein M. Renal sodium handling in liver disease. In: Epstein M, ed. The Kidney in Liver Disease. 4 ed. Philadelphia: Hanley and Belfus, 1996: 1-31
71. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109: 1917-1925
72. Gines P, Arroyo V. Paracentesis in the management of cirrhotic ascites. J Hepatol 1993; 17(Suppl 2): S14-S18
73. Møller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001; 36: 785-794
74. Jimenez-Saenz M, Ortiz-Moyano C, Cantillana-Martinez J, Herrerias-Gutierrez JM. Recurrent abdominal pain in systemic sclerosis: not always intestinal pseudo-obstruction. J Eur Acad Dermatol Venereol 2003; 17: 605-607
75. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15
76. Liu H, Song D, Lee SS. Cirrhotic cardiomyopathy. Gastroenterol Clin Biol 2002; 26: 842-847
77. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996; 24: 451-459
78. Kelbaek H, Rabol A, Brynjolf I, Eriksen J, Bonnevie O, Godtfredsen J, Munck O, Lund JO. Haemodynamic response to exercise in patients with alcoholic liver cirrhosis. Clin Physiol 1987; 7: 35-41
79. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 49: 268-275
80. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974; 49: 754-760
81. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger S. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996; 25: 135-144
82. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rossle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999; 44: 743-748
83. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, De CS, Riggio O. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002; 97: 142-148
84. Elizalde JI, Moitinho E, Garcia-Pagan JC, Cirera I, Escorsell A, Bandi JC, Jimenez W, Bosch J, Pique JM, Rodes J. Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. J Hepatol 1998; 29: 789-795
85. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, Hayes PC. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995; 22: 326-332
86. Møller S, Sondergaard L, Mogelvang J, Henriksen O, Henriksen JH. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 1995; 22: 472-478
87. Laffi G, Barletta G, La Villa G, Del Bene R, Riccardi D, Ticali P, Melani L, Fantini F, Gentilini P. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113: 891-898
88. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999; 97: 259-267
89. Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore P, Masini A, De Castro S, Merli M. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000; 95: 3200-3205
90. De BK, Majumdar D, Das D, Biswas PK, Mandal SK, Ray S, Bandopadhyay K, Das TK, Dasgupta S, Guru S. Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. J Hepatol 2003; 39: 315-319
91. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, Bolla GB, Roffi L, Failla M, Grassi G, Giannattasio C, Mancia G. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131-1137
92. Kelbaek H, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munck O, Bonnevie O, Godtfredsen J. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984; 54: 852-825
93. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, Castell J, Margarit C, Esteban R, Guardia J, Genesca J. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42: 68-74
94. Epstein SK, Ciubotaru RL, Zilberberg MD, Kaplan LM, Jacoby C, Freeman R, Kaplan MM. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci 1998; 43: 1701-1707
95. Friedman HS, Cirillo N, Schiano F, Nathan P, Khan S, Rosero H, Vaseghi M, Sacchi T, Vasavada B, Bjornson L. Vasodilatory state of decompensated cirrhosis: relation to hepatic dysfunction, ascites, and vasoactive substances. Alcohol Clin Exp Res 1995; 19: 123-129
96. Opie LH. The Heart. Physiology, from cell to circulation. 3 ed. Philadelphia: Lippincott, 1998
97. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996; 31: 279-284
98. Pozzi M, Grassi G, Ratti L, Favini G, Dell'Oro R, Redaelli E, Calchera I, Boari G, Mancia G. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 2005; 100: 1110-1116
99. Bos R, Mougenot N, Findji L, Mediani O, Vanhoutte PM, Lechat P. Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. J Cardiovasc Pharmacol 2005; 45: 8-13
100. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000; 6: S44-S52
101. Liu H, Song D, Lee SS. Cirrhotic cardiomyopathy. Gastroenterol Clin Biol 2002; 26: 842-847
102. Zavecz JH, Bueno O, Maloney RE, O'Donnell JM, Roerig SC, Battarbee HD. Cardiac excitation-contraction coupling in the portal hypertensive rat. Amer J Physiol Gastrointest Liver Physiol 2000; 279: G28-G39
103. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997; 273: G537-G544
104. Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet 1993; 341: 1423-1428
105. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34
106. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996; 23: 1128-1134
107. Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute nonselective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004; 40: 239-246
108. Hendrickse MT, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am J Gastroenterol 1994; 89: 750-757
109. Oliver MI, Miralles R, Rubies-Prat J, Navarro X, Espadaler JM, Sola R, Andreu M. Autonomic dysfunction in patients with non-alcoholic chronic liver disease. J Hepatol 1997; 26: 1242-1248
110. Trevisani F, Sica G, Mainqua P, Santese G, De Notariis S, Caraceni P, Domenicali M, Zaca F, Grazi GL, Mazziotti A, Cavallari A, Bernardi M. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 1999; 30: 1387-1392
111. Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am J Gastroenterol 2002; 97: 707-713
112. Dillon JF, Nolan J, Thomas H, Williams BC, Neilson JM, Bouchier IA, Hayes PC. The correction of autonomic dysfunction in cirrhosis by captopril. J Hepatol 1997; 26: 331-335
113. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M, Gasbarrini G. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol 1991; 12: 207-216
114. MacGilchrist AJ, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. Hepatology 1991; 13: 689-694
115. Arranz CT, Balaszczuk AM, Costa MA, Eizayaga FX, Romay S, Mongelli C, Lemberg A. Systemic baroreflex alterations in prehepatic portal hypertensive conscious rats. Arch Physiol Biochem 1995; 103: 422-426
116. La Villa G, Barletta G, Romanelli RG, Laffi G, Del Bene R, Vizzutti F, Pantaleo P, Mazzocchi V, Gentilini P. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology 2002; 35: 1441-1448
117. MacGilchrist AJ, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. Hepatology 1991; 13: 689-694
118. Moreau R, Hadengue A, Soupison T, Mechin G, Assous M, Roche-Sicot J, Sicot C. Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanisms. Hepatology 1990; 12: 7-12
119. Ryan J, Sudhir K, Jennings G, Esler M, Dudley F. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993; 105: 1167-1172
120. Hadengue A, Moreau R, Gaudin C, Bacq Y, Champigneulle B, Lebrec D. Total effective vascular compliance in patients with cirrhosis: a study of the response to acute blood volume expansion. Hepatology 1992; 15: 809-815
121. Andreu V, Perello A, Moitinho E, Escorsell A, Garcia-Pagan JC, Bosch J, Rodes J. Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. J Hepatol 2002; 36: 356-361
122. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index. Am J Physiol Gastrointest Liver Physiol 2001; 280: G584-594
123. Møller S, Gulberg V, Becker U, Gerbes AL, Henriksen JH. Elevated arterial compliance in patients with cirrhosis is not related to arterial endothelin-1. Scand J Gastroenterol 2002; 37: 1064-1069
124. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000; 20: 51-59
125. Rowell LB. Human cardiovascular control. Oxford: Oxford University Press, 1993
126. Salerno F, Cazzaniga M, Pagnozzi G, Cirello I, Nicolini A, Meregaglia D, Burdick L. Humoral and cardiac effects of TIPS in cirrhotic patients with different "effective" blood volume. Hepatology 2003; 38: 1370-1377
127. Rowell LB. Reflex control during orthostasis. In: Human cardiovascular control. ed. Oxford: Oxford University Press, 1993: 37-80
128. Mancia G, Mark AL. Arterial baroreflexes in humans. In: Berne RM, Sperelakis N, Geiger SR, eds. Handbook of Physiology. Vol III. The cardiovascular system.Peripheral circulation and organ blood flow. Baltimore: Waverly Press Inc., 1983: 755-793
129. Hendrickse MT, Thuluvath PJ, Triger DR. Natural history of autonomic neuropathy in chronic liver disease. Lancet 1992; 339: 1462-1464
130. Veglio F, Melchio R, Calva S, Rabbia F, Gallo V, Molino P, Mengozzi G, Mulatero P, Martini G, Riva P, Chiandussi L. Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. Liver 1998; 18: 420-426
131. Halliwill JR, Minson CT. Effect of hypoxia on arterial baroreflex control of heart rate and muscle sympathetic nerve activity in humans. J Appl Physiol 2002; 93: 857-864
132. Ogoh S, Volianitis S, Nissen P, Wray DW, Secher NH, Raven PB. Carotid baroreflex responsiveness to head-up tilt-induced central hypovolaemia: effect of aerobic fitness. J Physiol 2003; 551: 601-608
133. Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology 1997; 25: 1282-1284
134. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000; 32: 859-865
135. Henriksen JH, Møller S. Hypertension and liver disease. Curr Hypertens Rep 2004; 6: 453-461
136. Fernandez-Varo G, Ros J, Morales-Ruiz M, Cejudo-Martin P, Arroyo V, Sole M, Rivera F, Rodes J, Jimenez W. Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol 2003; 162: 1985-1993
137. Møller S, Norgaard A, Henriksen JH, Frandsen E, Bendtsen F. Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. Hepatology 2004; 40: 811-819
138. Agusti AG, Roca J, Bosch J, Rodriguez-Roisin R. The lung in patients with cirrhosis. J Hepatol 1990; 10: 251-257
139. Moreau R, Lee SS, Soupison T, Roche-Sicot J, Sicot C. Abnormal tissue oxygenation in patients with cirrhosis and liver failure. J Hepatol 1988; 7: 98-105
140. Agusti AG, Roca J, Rodriguez-Roisin R. Mechanisms of gas exchange impairment in patients with liver cirrhosis. Clin Chest Med 1996; 17: 49-66
141. Byrd RP Jr, Roy TM, Simons M. Improvement in oxygenation after large volume paracentesis. South Med J 1996; 89: 689-692
142. Krowka MJ. Hepatopulmonary syndromes. Gut 2000; 46: 1-4
143. Møller S, Hillingso J, Christensen E, Henriksen JH. Arterial hypoxaemia in cirrhosis: fact or fiction? Gut 1998; 42: 868-874
144. Martinez GP, Barbera JA, Visa J, Rimola A, Pare JC, Roca J, Navasa M, Rodes J, Rodriguez-Roisin R. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 2001; 34: 651-657
145. Rakela J, Krowka MJ. Cardiovascular and pulmonary complications of liver disease. In: Zakim D, Boyer TD, eds. Hepatology.A textbook of liver disease. 3 ed. Philadelphia: W.B.Saunders, 1996: 675-684
146. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Work Group on Standardization of Respiratory Function Tests. European Community for Coal and Steel. Official position of the European Respiratory Society. Rev Mal Respir 1994; 11 Suppl 3: 41-52
147. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153-1166
148. Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998; 114: 305-310
149. Rodriguez-Roisin R, Agusti AG, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 1992; 47: 897-902
150. Krowka MJ, Cortese DA. Hepatopulmonary syndrome. Current concepts in diagnostic and therapeutic considerations. Chest 1994; 105: 1528-1537
151. Fallon MB, Abrams GA, Luo B, Hou Z, Dai J, Ku DD. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997; 113: 606-614
152. Luo B, Liu L, Tang L, Zhang J, Stockard CR, Grizzle WE, Fallon MB. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol 2003; 38: 556-563
153. Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol 2005; 39: S138-S142
154. Soderman C, Leone A, Furst V, Persson MG. Endogenous nitric oxide in exhaled air from patients with liver cirrhosis. Scand J Gastroenterol 1997; 32: 591-597
155. Rolla G, Brussino L, Colagrande P, Dutto L, Polizzi S, Scappaticci E, Bergerone S, Morello M, Marzano A, Martinasso G, Salizzoni M, Bucca C. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997; 26: 842-847
156. Arguedas MR, Drake BB, Kapoor A, Fallon MB. Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology 2005; 128: 328-333
157. Rodriguez-Roisin R, Krowka MJ. Is severe arterial hypoxaemia due to hepatic disease an indication for liver transplantation? A new therapeutic approach. Eur Respir J 1994; 7: 839-842
158. Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, Muller C. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002; 51: 853-859
159. Krowka MJ. Portopulmonary hypertension and the issue of survival. Liver Transpl 2005; 11: 1026-1027
160. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24: 861-880
161. Abrams GA, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995; 109: 1283-1288
162. Aller R, Moya JL, Moreira V, Garcia-Lledo A, Sanroman AL, Paino C, Boixeda D. Diagnosis and grading of intrapulmonary vascular dilatation in cirrhotic patients with contrast transesophageal echocardiography. J Hepatol 1999; 31: 1044-1052
163. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41: 1122-1129
164. Riegler JL, Lang KA, Johnson SP, Westerman JH. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology 1995; 109: 978-983
165. Schwartz JM, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman DJ, Kowdley KV. Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: role of increased pulmonary artery pressure. J Clin Gastroenterol 2004; 38: 590-594
166. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41: 386-400
167. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-528
168. Katsuta Y, Zhang XJ, Kato Y, Shimizu S, Komeichi K, Ohsuga M, Higashi H, Satomura K, Takano T. Hemodynamic features and impaired arterial oxygenation in patients with portopulmonary hypertension. Hepatol Res 2005:
169. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005; 128: 164-168
170. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25: 502-508